Objective responses, good safety and evidence of stimulation of the immune system observed under murlentamab (GM102) single agent and in combination with chemotherapy Read more
GM102, a first-in-class monoclonal glyco-engineered antibody (Ab) targeting Anti-Mullerian – Hormone-Receptor II (AMHRII): safety and hints of activity in Granulosa Cell Tumors (GCT)
GM102, a low fucosylated anti-Müllerian Hormone type II Receptor (AMHRII) antibody promotes in vitro anti-tumoral activities of innate (macrophages) and adaptative (CD4+ and CD8+ T cells) immune cells
GamaMabs Pharma to present new data on GM102 at two upcoming scientific conferences in November
New clinical data in Granulosa Cell Tumor (GCT) patients will be presented at the EORTC–NCI–AACR 2018 Symposium and GM102 unique T-cell activation mechanism at the AACR 2018 Conference on Tumor Immunology and Immunotherapy
GamaMabs Pharma starts a phase 2 study of monoclonal antibody GM102 in patients with advanced or metastatic colorectal cancer
C201 phase 2 will study immuno-enhancer antibody GM102, targeting AMHRII as a single agent and in combination with Trifluridine/Tipiracil (Lonsurf®)
A First-In Human study of monoclonal antibody GM102 in patients with Anti-Müllerian-Hormone-Receptor II (AMHRII) positive gynecological cancers
GamaMabs Pharma to present at 2018 ASCO annual meeting results from the First-In-Human clinical study of GM102 in advanced gynecological cancers
Objective responses, good safety and evidence of stimulation of the immune system were observed with GM102 administered as a single agent in the dose-finding escalation part of the study
A first-in-human study of monoclonal antibody GM102 in patients with anti- Mullerian-hormone-receptor II (AMHRII) positive gynecological cancers.
Abstract # 5542_Presented Monday, June 4, 2018
AACR 2018: GamaMabs Pharma to present new data on expression of Anti-Müllerian Hormone type II Receptor in non-gynecological cancers and on first ADC candidate targeting AMHRII
AMHRII expression and Antibody-Drug Conjugate preclinical data suggest potential broader applications for anti-AMHRII-based therapy
GamaMabs Pharma receives Orphan Drug Designation from US FDA for lead compound GM102
This designation has been awarded for the treatment of AMHR2-expressing ovarian cancers, exclusive of AMHR2-expressing fallopian tube cancers and primary peritoneal cancers